Format

Send to

Choose Destination
BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1.

PARP inhibitors in the management of breast cancer: current data and future prospects.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. luca_livraghi@dfci.harvard.edu.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. judy_garber@dfci.harvard.edu.

Abstract

Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers. We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.

PMID:
26268938
PMCID:
PMC4535298
DOI:
10.1186/s12916-015-0425-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center